Bioxyne Limited Stock

Equities

BXN

AU000000BXN6

Biotechnology & Medical Research

Market Closed - Australian S.E. 08:21:08 2024-04-28 pm EDT 5-day change 1st Jan Change
0.008 AUD 0.00% Intraday chart for Bioxyne Limited -11.11% -27.27%
Sales 2022 2.48M 1.63M Sales 2023 5.3M 3.48M Capitalization 38.03M 24.98M
Net income 2022 - 0 Net income 2023 -1M -657K EV / Sales 2022 2.22 x
Net cash position 2022 2.17M 1.42M Net cash position 2023 3.29M 2.16M EV / Sales 2023 6.55 x
P/E ratio 2022
-30.1 x
P/E ratio 2023
-13.9 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 22.01%
More Fundamentals * Assessed data
Dynamic Chart
1 week-11.11%
Current month-33.33%
1 month-27.27%
3 months-46.67%
6 months-33.33%
Current year-27.27%
More quotes
1 week
0.01
Extreme 0.007
0.01
1 month
0.01
Extreme 0.007
0.01
Current year
0.01
Extreme 0.007
0.02
1 year
0.01
Extreme 0.007
0.03
3 years
0.01
Extreme 0.007
0.04
5 years
0.01
Extreme 0.007
0.04
10 years
0.01
Extreme 0.005
0.14
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-05-18
Comptroller/Controller/Auditor - -
Members of the board TitleAgeSince
Chairman 65 12-10-29
Director/Board Member - 23-05-18
Chief Executive Officer - 23-05-18
More insiders
Date Price Change Volume
24-04-28 0.008 0.00% 80 000
24-04-26 0.008 +14.29% 313,973
24-04-24 0.007 -12.50% 241,830
24-04-23 0.008 -11.11% 715,246

Delayed Quote Australian S.E., April 28, 2024 at 08:21 pm EDT

More quotes
Bioxyne Limited is an Australia-based health and wellness products company. Its activity is the development, manufacture and distribution of nutritional health and wellness supplements through indirect wholesale and direct sales channels in the health and wellness sector. It is engaged in the consumer dietary supplements and functional foods markets through its probiotic, Lactobacillus fermentum VRI-003 (PCC). The Company has developed a range of functional food and beauty products containing ingredients sourced primarily from New Zealand, through its direct sales business trading as Bioxyne International. It has an interest in Breathe Life Sciences (BLS). It has operations across Australia, the United Kingdom, Japan, Europe and Southeast Asia with a health and wellness product portfolio, including health supplements, skincare, probiotics, cannabis-derived raw materials, starting materials, active pharmaceutical ingredients, cannabinoid-based therapies and telemedicine technology.
More about the company